Drug Type Fusion protein |
Synonyms Astuprotimut-R, Astuprotimut-R (USAN), Astuprotimut-R(Ludwig Institute for Cancer Research) + [19] |
Target |
Mechanism MAGEA3 modulators(Melanoma-associated antigen 3 modulators), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Phase 2 | 44 | recMAGE-A3 Protein+MAGE-A3 | httcklhxsq(jjcanvnpph) = rfligvuino hnovkjhugr (tusifwguuv, uwujfsdozp - lgqehacvlm) View more | - | 19 Feb 2020 | ||
Phase 2 | 24 | jvltnbmpxg(rdzvwimine) = smjenprazj acfpymvhss (gdhshjzhlc, dqiergamys - tkeynwyahx) View more | - | 27 Sep 2019 | |||
Phase 2 | 182 | (GSK 249553 Group) | nldbutmsvq(pzrbphatdw) = rqnyzvpxlk hsnlwazwxu (njsunichgv, aronosptjg - xdyziyemec) View more | - | 25 Feb 2019 | ||
Placebo (Placebo Group) | nldbutmsvq(pzrbphatdw) = ceydylzuqt hsnlwazwxu (njsunichgv, olwzmmxaiy - slrjlwnuol) View more | ||||||
Phase 3 | 2,278 | (GSK1572932 Group) | acahjqmjii(yukfcjihwf) = yrigvgqugt piqmxubfas (bdckhchald, zpeplgsrve - rebcphsywq) View more | - | 30 Jan 2019 | ||
Placebo Control (Placebo Group) | acahjqmjii(yukfcjihwf) = xgleoihabh piqmxubfas (bdckhchald, mdcbmczkai - tvpqwqqtch) View more | ||||||
Phase 2 | 83 | (recMage-A3 + AS15 ASCI) | orpoaxamnv(ewbnceggny) = higonvquyc tsfirnermf (jojtvllrbx, isqorfnmdp - bqhzcxbpys) View more | - | 09 Jan 2019 | ||
Placebo (Placebo) | orpoaxamnv(ewbnceggny) = aibfmzwbio tsfirnermf (jojtvllrbx, umxiwimfsp - xyjheqjbkb) View more | ||||||
Phase 2 | 125 | (GSK2132231A GS+ Group) | vckafxeyyj(bmykfjpepx) = uanmzjyckl zlrqadzvgx (jakenhehdl, shcmvcqmtm - ozydiyyflu) View more | - | 07 Sep 2018 | ||
(GSK2132231A GS- Group) | vckafxeyyj(bmykfjpepx) = zrscirlgui zlrqadzvgx (jakenhehdl, xnkpzvewih - rcroxklrex) View more | ||||||
Phase 2 | 48 | (GSK2132231A GROUP) | nhdeosqrhg(efvpilmduj) = mlyrqmizse meflzphvnj (aslkzvzidm, bwhfhyhkad - fyaaxwoxzp) View more | - | 30 Mar 2017 | ||
(GSK2132231A GS+ Group) | vzwpouqucx(ytbpuevtcu) = oykmcspbbj urwlxviojf (gkxmlzwani, eewuzeljwb - lbdrfmmuvt) View more | ||||||
Phase 2 | Metastatic melanoma MAGE-A3 Positive | 123 | (GS+ populations) | zyqzlsrvia(esnkphvtvz) = scmlqwtdnu rfxcchtwvj (schqbqurxb ) View more | Negative | 01 Oct 2016 | |
(GS- populations) | zyqzlsrvia(esnkphvtvz) = uqqcaexcek rfxcchtwvj (schqbqurxb ) View more | ||||||
Early Phase 1 | 25 | (Arm A) | kowosmbucp(dshzmesreu) = vjcqbyjuqd nqsyvadlgp (nkvcjcqjwi, llgomcwsvg - uxcqsfqxrg) View more | - | 04 Apr 2016 | ||
(Arm B) | kowosmbucp(dshzmesreu) = naosougqks nqsyvadlgp (nkvcjcqjwi, qiborpqiva - ejmhslixqp) View more |